Halozyme Therapeutics, Inc.HALONASDAQ
Loading
P/E Ratio: Premium ValuationElevated
Percentile Rank79
3Y CAGR-12.9%
5Y CAGR-10.8%
Year-over-Year Change
Price-to-earnings ratio
3Y CAGR
-12.9%/yr
Annual compound
5Y CAGR
-10.8%/yr
Consistent
Percentile
P79
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
1 yr
Consecutive growthElevated
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 25.45 | +86.4% |
| 2024 | 13.65 | -21.1% |
| 2023 | 17.32 | -55.0% |
| 2022 | 38.52 | +174.3% |
| 2021 | 14.04 | -68.8% |
| 2020 | 45.07 | +227.2% |
| 2019 | -35.42 | -35.6% |
| 2018 | -26.12 | -159.5% |
| 2017 | 43.89 | +459.8% |
| 2016 | -12.20 | - |